Herlitz J, Pennert K, Wedel H, Vedin A, Wilhelmsson C, Wilhelmsen L, Hjalmarson A
Am J Cardiol. 1984 Jun 25;53(13):46D-50D.
During a 3-month follow-up, 131 patients (19.1%) withdrew from blind treatment in both metoprolol- and placebo-treated groups. More metoprolol-treated than placebo-treated patients withdrew because of cardiovascular adverse experience mainly during the very early phase. In all, 45 (6.5%) metoprolol-treated vs 14 (2.0%) placebo-treated patients were not given either a full intravenous dose or a full oral dose 15 minutes later. Bradycardia and hypotension were more common in the metoprolol group, whereas severe atrioventricular block did occur in a similar number of patients in both groups and severe congestive heart failure was more common in the placebo group. Results indicate that tolerance is generally good after intravenous and oral treatment with metoprolol in patients with suspected acute myocardial infarction.
在3个月的随访期间，美托洛尔治疗组和安慰剂治疗组中均有131例患者（19.1%）退出盲法治疗。因心血管不良事件退出治疗的美托洛尔治疗组患者多于安慰剂治疗组患者，主要发生在极早期。总体而言，美托洛尔治疗组有45例患者（6.5%）未在15分钟后给予全静脉剂量或全口服剂量，而安慰剂治疗组有14例患者（2.0%）未给予。心动过缓和低血压在美托洛尔组更为常见，而严重房室传导阻滞在两组中发生的患者数量相似，严重充血性心力衰竭在安慰剂组更为常见。结果表明，疑似急性心肌梗死患者经美托洛尔静脉和口服治疗后耐受性总体良好。
